Tags » Renal Cell Carcinoma

Cellectar Biosciences Reports First Quarter 2015 Financial Results and Provides Update on Clinical Programs

MADISON, Wis., May 21, 2015 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an update on its development programs and financial results for the first quarter 2015. 1,117 more words

Preclinical & Clinical

PsiOxus Therapeutics Raises a £25M Series C Investment to Progress Oncolytic Virus Plus Checkpoint Inhibitor Combination Study in Metastatic Colorectal Cancer

OXFORD, England–(BUSINESS WIRE)–PsiOxus Therapeutics Ltd. (PsiOxus), the oncolytic immuno-oncology company, has closed a Series C financing round of £25 million (c$38.5 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes from the antibody ‘armed’ series of AbEnAd viruses. 648 more words

Ovarian Cancer

Provectus Biopharmaceuticals Extends for Additional 60 Days Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm a-Think Pharmaceutical Co., Ltd

KNOXVILLE, TN–(BUSINESS WIRE)–Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), today announced that it had extended for an additional 60 days its Memorandum of Understanding with with Sinopharm-China State Institute of Pharmaceutical Industry (“Sinopharm-CSIPI”), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. 457 more words

Pancreatic Cancer

Foundation Medicine and Collaborators to Present Data in 22 Oral and Poster Presentations at the 2015 ASCO Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present 22 oral and poster presentations at the 2015 American Society for Clinical Oncology (ASCO) Annual Meeting taking place May 29 – June 2, 2015 in Chicago. 1,811 more words

Scientific Conferences & Presentations

Remission day

There was over cast this morning but as the sun was expected over the horizon at 5:37 am I waited for day break to mark my 8th year in remission. 260 more words

New Data Show Proleukin® (aldesleukin) Improves Patient Outcomes as First-Line Therapy for the Treatment of Patients with Metastatic Melanoma or Metastatic Renal Cell Carcinoma

SAN DIEGO, May 15, 2015 /PRNewswire/ — Prometheus Laboratories Inc. today announced the acceptance of data from three clinical studies by the American Society of Clinical Oncology (ASCO) for their 51st annual meeting, to be held May 29 through June 2 in Chicago, IL.   1,260 more words

Preclinical & Clinical

Sevion Therapeutics Reports Third Quarter 2015 Financial Results

SAN DIEGO–(BUSINESS WIRE)–Sevion Therapeutics, Inc. (“Sevion” or the “Company”) (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal quarter ended March 31, 2015 (“Third Quarter 2015”). 472 more words

Preclinical & Clinical